康希諾(688185.SH):吸附無細胞百(組分)白破聯合疫苗(6歲及以上人羣用)啟動I期臨牀試驗並完成首例受試者入組
格隆匯12月6日丨康希諾(688185.SH)公佈,公司的吸附無細胞百(組分)白破聯合疫苗(6歲及以上人羣用)於近日正式啟動I期臨牀試驗,並完成首例受試者入組。青少年及成人用Tdcp適用於6歲及以上人羣,為青少年及成人的百白破加強疫苗,主要發達國家已將該疫苗納入常規的疫苗接種計劃,但國內並無獲批的青少年及成人用百白破加強疫苗,該產品若成功上市,將填補國內市場空白。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.